GTC Biotherapeutics (fka GTCB)

[wjlknew]

Pharming signs distribution agreement for Rhucin in Turkey.

"Leiden, The Netherlands, March 25, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it has signed an exclusive licensing and distribution agreement with EIP Eczacibasi Ilaç Pazarlama A.S., (EIP) a leading Turkish pharmaceutical company for the marketing and sales of Rhucin® in Turkey. The agreement covers the use of Rhucin® to treat acute attacks of Hereditary Angioedema (HAE) with a right of first refusal to EIP for other indications.

EIP will be responsible for registration of the product in Turkey and has already taken the first steps in this process. Rhucin® may be eligible for an accelerated review procedure given the high medical need for new therapies in the HAE-patient community as a life threatening disease. Data submitted to the EMEA as well as additional data generated after the EMEA-submission will be used in the registration procedure, although the decision on registration in Turkey will be independent of decisions made in the EU or the USA. Under the terms of the agreement, EIP will purchase the product from Pharming and market, sell and distribute it in Turkey. EIP will also pay a license fee to Pharming for the product."

http://biz.yahoo.com/iw/080325/0378925.html